| 宋鑫,魏立强,郭文渊,等.卡培他滨联合奥沙利铂治疗复发转移性胃癌的效果[J].中国临床保健杂志,2020,23(1):133-135. |
| 卡培他滨联合奥沙利铂治疗复发转移性胃癌的效果 |
| Clinical analysis of capecitabine combined with oxaliplatin for recurrent or metastatic gastric cancer |
| 投稿时间：2019-09-20 |
| DOI：10.3969/J.issn.1672-6790.2020.01.031 |
| 中文关键词: 胃肿瘤 肿瘤复发,局部 肿瘤转移 卡培他滨 铂化合物 顺铂 |
| 英文关键词: Stomach neoplasms Neoplasm recurrence,local Neoplasm metastasis Capecitabine Platinum compounds Cisplatin |
| 基金项目: |
|
| 摘要点击次数: 5283 |
| 全文下载次数: 5584 |
| 中文摘要: |
| 目的 探讨卡培他滨联合奥沙利铂(XELOX)化疗方案治疗复发或转移性胃癌的疗效和安全性。方法 将94例复发或转移性胃癌患者按照随机数字表法分为对照组和观察组各47例。对照组予卡培他滨联合顺铂(XP)化疗方案,观察组予XELOX化疗方案,21 d为一个疗程,至少治疗2个疗程后评价疗效,比较疗效、卡氏功能状态(KPS)评分,记录毒性作用。结果 两组化疗方案对局部复发或淋巴转移、软组织转移疗效较好；组间相比,观察组肝转移的疾病控制率为70.0%,高于对照组的46.2%(P<0.05)。两组主要毒副反应为骨髓抑制和胃肠道反应,可耐受。观察组Ⅲ度及以上无恶心呕吐发生,对照组为12.8%。绘制两组的PFS及OSKaplan-meier生存曲线并经Log-rank法比较发现两组的生存情况差异均无统计学意义(P＞0.05)。结论 XELOX化疗方案治疗复发或转移性胃癌疗效肯定且耐受性较好。 |
| 英文摘要: |
| Objective To explore the clinical effects and safety of capecitabine combined with oxaliplatin (XELOX) regime for recurrent or metastatic gastric cancer.Methods 94 patients with recurrent or metastatic gastric cancer were randomly divided into control group (47 cases) and study group (47 cases).The control group received Capecitabine and cisplatin (XP) regime,the study group received XELOX regime,the treatment cycle was 21 days,and the efficacy (ORR and DCR) was evaluated after at least 2 cycles.The efficacy and KPS score were compared,toxic reactions were recorded,and the follow-up was carried out after treatment.Results The two regimes showed good clinical effects for regional recurrence,lymphatic metastasis and soft tissue metastasis.For study group,the DCRs for liver metastasis was 70.0%,which were higher than that of 46.2% in control group (P<0.05).The toxic reactions in two groups were mainly myelosuppression and gastrointestinal tract reactions,which were tolerable.No patient had nausea and vomiting of grade 3 in study group,which was 12.8% in control group.There was no significant difference in the survival curves of PFS and OSKaplan-meier between two groups (P>0.05).Conclusion XELOX regime is effective and well tolerated treatment for patients with recurrent or metastatic gastric cancer. |
|
查看全文
|
| 关闭 |
|
|
|